TCM
ABBV icon

Traynor Capital Management’s AbbVie ABBV Stock Holding History

Traynor Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.9M Sell
19,460
-1,481
-7% -$319K 0.23% 60
2026
Q1 		$4.46M Buy
20,941
+1,281
+7% +$284K 0.26% 62
2025
Q4 		$4.49M Buy
19,660
+7
+0% +$1.59K 0.24% 61
2025
Q3 		$4.55M Buy
19,653
+13,555
+222% +$2.76M 0.26% 58
2025
Q2 		$1.16M Sell
6,098
-428
-7% -$79.5K 0.08% 82
2025
Q1 		$1.37M Buy
6,526
+215
+3% +$41.8K 0.12% 79
2024
Q4 		$1.12M Buy
6,311
+686
+12% +$126K 0.07% 92
2024
Q3 		$1.11M Buy
5,625
+837
+17% +$156K 0.07% 99
2024
Q2 		$821K Buy
4,788
+476
+11% +$78.8K 0.06% 101
2024
Q1 		$785K Buy
4,312
+198
+5% +$34.1K 0.07% 112
2023
Q4 		$638K Buy
4,114
+322
+8% +$46.9K 0.07% 118
2023
Q3 		$565K Sell
3,792
-378
-9% -$55.5K 0.07% 114
2023
Q2 		$562K Buy
4,170
+22
+0.5% +$3.23K 0.07% 117
2023
Q1 		$661K Buy
4,148
+552
+15% +$84.4K 0.1% 108
2022
Q4 		$581K Buy
3,596
+173
+5% +$26.5K 0.08% 119
2022
Q3 		$459K Buy
3,423
+252
+8% +$36.2K 0.08% 100
2022
Q2 		$485K Sell
3,171
-735
-19% -$112K 0.08% 97
2022
Q1 		$633K Buy
3,906
+6
+0.2% +$872 0.08% 101
2021
Q4 		$528K Sell
3,900
-360
-8% -$42.5K 0.06% 126
2021
Q3 		$459K Buy
4,260
+426
+11% +$48.7K 0.06% 123
2021
Q2 		$441K Buy
3,834
+171
+5% +$19.3K 0.06% 120
2021
Q1 		$396K Buy
3,663
+858
+31% +$91.8K 0.07% 115
2020
Q4 		$300K Sell
2,805
-1,869
-40% -$180K 0.05% 119
2020
Q3 		$394K Buy
4,674
+50
+1% +$4.71K 0.09% 103
2020
Q2 		$454K Buy
4,624
+449
+11% +$39.5K 0.11% 95
2020
Q1 		$318K Sell
4,175
-1,520
-27% -$129K 0.11% 89
2019
Q4 		$504K Buy
5,695
+194
+4% +$16.1K 0.13% 96
2019
Q3 		$416K Buy
5,501
+451
+9% +$30.9K 0.13% 103
2019
Q2 		$370K Sell
5,050
-1,228
-20% -$96.5K 0.12% 106
2019
Q1 		$505K Sell
6,278
-352
-5% -$28.8K 0.17% 89
2018
Q4 		$611K Buy
6,630
+887
+15% +$78K 0.25% 65
2018
Q3 		$543K Buy
5,743
+577
+11% +$54.7K 0.18% 84
2018
Q2 		$480K Sell
5,166
-1,137
-18% -$111K 0.18% 87
2018
Q1 		$596K Buy
6,303
+1,164
+23% +$128K 0.24% 72
2017
Q4 		$497K Buy
5,139
+61
+1% +$5.75K 0.21% 87
2017
Q3 		$451K Buy
5,078
+130
+3% +$9.9K 0.21% 90
2017
Q2 		$355K Sell
4,948
-1,668
-25% -$112K 0.18% 107
2017
Q1 		$499K Buy
+6,616
New +$416K 0.28% 74
2016
Q4 		– Sell
-3,345
Closed -$205K – 131
2016
Q3 		$205K Buy
+3,345
New +$217K 0.14% 113

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

Traynor Capital Management's ABBV Position: Q2 2026 in Review

Traynor Capital Management reduced its AbbVie (ABBV) stake by 7.1% in Q2 2026, selling an estimated $319K and leaving 19,460 shares worth $4.9M. The position accounts for 0.23% of the portfolio, ranked #60.

Traynor Capital Management first reported a position in ABBV in Q3 2016 and has held it in 39 quarters since. 1,453 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Traynor Capital Management held 19,460 shares of AbbVie worth $4.9M as of Q2 2026.
  • Traynor Capital Management sold 1,481 AbbVie shares in Q2 2026, an estimated $319K.
  • AbbVie made up 0.23% of Traynor Capital Management's portfolio in Q2 2026, its #60 holding.
  • Traynor Capital Management first reported a position in AbbVie in Q3 2016 and has held it in 39 quarters since.
  • 1,453 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.